Tags

Type your tag names separated by a space and hit enter

Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Arterioscler Thromb Vasc Biol. 2006 Dec; 26(12):2793-9.AT

Abstract

OBJECTIVE

To get a better insight into the role of hemostasis in coronary artery disease (CAD), we assessed the impact of von Willebrand factor (vWF), fibrinogen, thrombin-antithrombin (TAT) complexes, D-dimers, and plasmin-antiplasmin (PAP) complexes on the risk of cardiovascular event in a prospective cohort of CAD patients.

METHODS AND RESULTS

The prospective Atherogene cohort includes 1057 individuals with an angiographically proven coronary artery disease at baseline. After a median follow-up of 6.6 years, 135 individuals died from a cardiovascular cause and 97 had a nonfatal cardiovascular event. Higher levels of all 5 hemostatic markers at baseline were associated with an increased risk of cardiovascular death, but not of nonfatal event. Except for vWF, these associations remained significant after adjustment for conventional cardiovascular risk factors and C-reactive protein (CRP) levels (P for trend according to increasing tertiles=0.20, 0.011, 0.026, 0.019, and 0.01 for vWF, fibrinogen, TAT, D-Dimer, and PAP, respectively). When including the 5 hemostatic markers in a stepwise Cox regression analysis where conventional risk factors and CRP were forced into the model, fibrinogen and D-dimers remained independently associated with the risk of cardiovascular death. Adjusted hazard ratios (95% CI) associated with one SD increase of fibrinogen and D-dimers were 1.27 (1.04 to 1.55) and 1.29 (1.09 to 1.53), respectively.

CONCLUSIONS

In patients with coronary artery disease, fibrinogen and D-dimer levels are independent predictors of subsequent cardiovascular death. Our data support a role of impaired coagulation/fibrinolysis process in the complications of coronary artery disease.

Authors+Show Affiliations

INSERM UMR S 525 and Université Pierre et Marie Curie-Paris 6, Paris, France. pmorange@ap-hm.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17023678

Citation

Morange, P E., et al. "Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease: the AtheroGene Study." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 12, 2006, pp. 2793-9.
Morange PE, Bickel C, Nicaud V, et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol. 2006;26(12):2793-9.
Morange, P. E., Bickel, C., Nicaud, V., Schnabel, R., Rupprecht, H. J., Peetz, D., Lackner, K. J., Cambien, F., Blankenberg, S., & Tiret, L. (2006). Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(12), 2793-9.
Morange PE, et al. Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease: the AtheroGene Study. Arterioscler Thromb Vasc Biol. 2006;26(12):2793-9. PubMed PMID: 17023678.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. AU - Morange,P E, AU - Bickel,C, AU - Nicaud,V, AU - Schnabel,R, AU - Rupprecht,H J, AU - Peetz,D, AU - Lackner,K J, AU - Cambien,F, AU - Blankenberg,S, AU - Tiret,L, AU - ,, Y1 - 2006/10/05/ PY - 2006/10/7/pubmed PY - 2006/12/28/medline PY - 2006/10/7/entrez SP - 2793 EP - 9 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler Thromb Vasc Biol VL - 26 IS - 12 N2 - OBJECTIVE: To get a better insight into the role of hemostasis in coronary artery disease (CAD), we assessed the impact of von Willebrand factor (vWF), fibrinogen, thrombin-antithrombin (TAT) complexes, D-dimers, and plasmin-antiplasmin (PAP) complexes on the risk of cardiovascular event in a prospective cohort of CAD patients. METHODS AND RESULTS: The prospective Atherogene cohort includes 1057 individuals with an angiographically proven coronary artery disease at baseline. After a median follow-up of 6.6 years, 135 individuals died from a cardiovascular cause and 97 had a nonfatal cardiovascular event. Higher levels of all 5 hemostatic markers at baseline were associated with an increased risk of cardiovascular death, but not of nonfatal event. Except for vWF, these associations remained significant after adjustment for conventional cardiovascular risk factors and C-reactive protein (CRP) levels (P for trend according to increasing tertiles=0.20, 0.011, 0.026, 0.019, and 0.01 for vWF, fibrinogen, TAT, D-Dimer, and PAP, respectively). When including the 5 hemostatic markers in a stepwise Cox regression analysis where conventional risk factors and CRP were forced into the model, fibrinogen and D-dimers remained independently associated with the risk of cardiovascular death. Adjusted hazard ratios (95% CI) associated with one SD increase of fibrinogen and D-dimers were 1.27 (1.04 to 1.55) and 1.29 (1.09 to 1.53), respectively. CONCLUSIONS: In patients with coronary artery disease, fibrinogen and D-dimer levels are independent predictors of subsequent cardiovascular death. Our data support a role of impaired coagulation/fibrinolysis process in the complications of coronary artery disease. SN - 1524-4636 UR - https://www.unboundmedicine.com/medline/citation/17023678/Haemostatic_factors_and_the_risk_of_cardiovascular_death_in_patients_with_coronary_artery_disease:_the_AtheroGene_study_ L2 - https://www.ahajournals.org/doi/10.1161/01.ATV.0000249406.92992.0d?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -